Share

    


Home / Search Results

Search Results

You searched for:

In addition to the global pandemic, ongoing lawsuits from referenced biologics' manufacturers suing biosimilar manufacturers are having a negative impact on the development and approval of new biosimilars.
Put yourself first: this mantra is especially important today as we continue to grapple with the implications and fallout from the COVID-19 global pandemic.
Assuming the ACCC presidency in March of 2020, just as the COVID-19 public health emergency went into effect, was certainly a dramatic way to enter office. That said, I am pleased with how much we have accomplished these last 12 months— despite the nationwide shutdown and ongoing pandemic.
As we turn the corner toward 2022, for oncology to drive equity forward: We need every member and every discipline, patient, leader, payer, industry partner, and innovator working together to provide the most equitable care possible in a sustainable way.